Search & Analyze

Rubicon Research Ltd.

HealthcarePharmaceuticals & Drugs

www.rubicon.co.in BSE: 544578NSE: RUBICON

₹1,763.75BSE2.66%

16 Sep, 4:01 PM

₹1,763.75

₹29.20K Cr

101.30

21.75

27.84%

₹1,812.70

₹1,716.40

₹1,896.15

₹571.00

Customise metrics bar

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,853.50	36.77	4,44,716.74	0.86	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	9,199.70	83.50	2,44,223.13	0.33	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,823.05	84.11	1,83,453.32	0.79	566.00	3.28%	4,921.00	54.85%	19.27
ZYDUSLIFE ZYDUSLIFE	1,105.00	24.42	1,10,224.17	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,359.75	32.59	1,09,848.55	0.96	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,906.00	94.19	1,02,983.51	0.10	362.07	123.94%	2,026.31	29.10%	18.20
DR.REDDY'S DRREDDY	1,145.25	29.67	95,591.76	0.70	435.60	-69.10%	8,099.80	-5.51%	13.75
Rubicon Research Ltd. RUBICON	1,763.75	101.30	29,195.69	0.09	84.78	95.79%	534.34	51.59%	29.22

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	296.01	313.40	358.15	352.49	412.02	475.53	513.92	534.34
Expenses	234.35	243.50	285.67	273.38	317.72	367.40	395.21	405.22
	61.66	69.90	72.48	79.11	94.30	108.13	118.70	129.12
	20.83%	22.30%	20.24%	22.44%	22.89%	22.74%	23.10%	24.16%
	2.66	0.49	0.10	0.63	0.70	3.79	2.61	5.68
Interest	7.02	7.82	11.85	10.62	11.42	9.77	10.36	9.29
	8.15	9.42	9.66	9.57	11.87	11.55	12.27	15.14
	49.15	53.15	51.06	59.56	71.71	90.59	98.69	110.37
	29.86%	28.37%	29.01%	27.29%	24.90%	19.64%	22.19%	23.19%
	34.48	38.07	36.25	43.30	53.85	72.80	76.79	84.78
	2.24	2.50	2.35	2.81	3.49	4.42	4.65	5.13

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	313.57	393.52	853.89	2,397.66	3,785.57
	313.57	393.52	853.89	1,284.27	1,753.96
EXPENDITURE :
Increase/Decrease in Stock	-17.05	-49.25	-53.01	-157.22	-150.37
Raw Material Consumed	82.13	149.40	309.33	488.95	634.42
Power & Fuel Cost	10.51	15.71	18.62	20.38	25.09
Employee Cost	78.90	97.12	125.34	211.05	256.29
Other Manufacturing Expenses	95.82	64.47	59.84	151.73	226.18
General and Administration Expenses	74.58	55.98	96.91	135.98	181.76
Selling and Distribution Expenses	20.71	33.93	130.53	167.17	163.31
Miscellaneous Expenses	7.19	7.66	11.75	10.30	18.01
	352.80	375.03	699.30	1,028.33	1,354.69
Operating Profit (Excl OI)	-39.23	18.49	154.59	255.95	399.26
	16.85	25.48	18.50	11.95	8.70
	-22.38	43.97	173.09	267.89	407.96
Interest	9.72	18.96	31.26	36.78	42.17
PBDT	-32.11	25.01	141.83	231.11	365.80
	34.01	36.06	38.97	36.59	45.26
Profit Before Taxation & Exceptional Items	-66.11	-11.05	102.86	194.52	320.53
	-66.11	-11.05	102.86	194.52	320.53
Provision for Tax	1.01	5.84	11.85	60.16	73.80
	-67.12	-16.89	91.01	134.36	246.74
Extra items			0.00	0.00	0.00
Consolidated Net Profit	-67.12	-16.89	91.01	134.36	246.74
Profit Balance B/F	110.11	42.49	25.34	116.10	252.11
Appropriations	42.99	25.60	116.36	250.46	498.85
Equity Dividend %	15.00%	5.00%	2.00%	2.00%	150.00%
	-132.38	-33.31	5.98	8.72	14.95
Adjusted EPS	-4.41	-1.11	5.98	8.72	14.95

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	5.07	5.07	15.21	15.41	16.51
Share Warrants & Outstandings	12.23	14.56	23.78	26.27	31.32
Total Reserves	288.10	266.75	346.02	499.30	1,240.99
Reserve excluding Revaluation Reserve	288.10	266.75	346.02	499.30	1,240.99
Revaluation reserve	0.00	0.00	0.00
	305.40	286.38	385.00	540.98	1,288.82
Minority Interest				0.00	0.00
Secured Loans	63.42	97.28	92.61	64.47	143.02
Unsecured Loans	0.36
Deferred Tax Assets / Liabilities	3.90	1.45	-0.93	-1.77	-13.01
Other Long Term Liabilities	1.56		55.00	50.40	47.37
Long Term Provisions	1.36	3.28	4.39	9.55	11.64
Total Non-Current Liabilities	70.61	102.01	151.06	122.65	189.02
Trade Payables	56.97	96.87	176.74	239.12	377.46
Other Current Liabilities	32.76	45.77	75.11	93.02	153.72
Short Term Borrowings	91.36	195.79	264.22	290.12	67.70
Short Term Provisions	2.43	22.89	56.43	163.77	236.98
Total Current Liabilities	183.51	361.32	572.50	786.03	835.87
Total Liabilities	559.52	749.70	1,108.56	1,449.66	2,313.71
Gross Block	316.51	358.99	491.76	540.00	787.79
Less: Accumulated Depreciation	123.52	159.61	184.54	213.09	255.83
Net Block	192.98	199.38	307.22	326.91	531.96
Capital Work in Progress	2.64	24.51	9.58	6.67	40.46
Non Current Investments	0.05	0.05	0.05	0.05	26.59
Long Term Investment	0.05	0.05	0.05	0.05	26.59
Long Term Loans & Advances	28.21	13.10	15.67	40.87	25.24
Other Non Current Assets	7.24	11.09	12.77	11.55	7.51
Total Non-Current Assets	231.12	248.12	345.40	386.29	631.90
Inventories	89.59	167.21	300.49	521.61	728.99
Sundry Debtors	139.57	224.98	301.47	323.79	508.71
Cash and Bank	52.60	58.91	58.39	116.23	346.02
Other Current Assets	28.95	19.01	49.21	63.59	51.63
Short Term Loans and Advances	17.69	31.48	53.61	38.14	46.46
Total Current Assets	328.40	501.59	763.17	1,063.37	1,681.81
Net Current Assets (Including Current Investments)	144.89	140.27	190.67	277.34	845.94
Total Assets	559.52	749.70	1,108.56	1,449.66	2,313.71
Contingent Liabilities	2.01	9.05	10.24	12.25	19.09
Total Debt	169.56	317.91	396.41	393.17	259.37
	578.25	536.12	23.75	33.39	76.17
Adjusted Book Value	19.27	17.87	23.75	33.39	76.17

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	-66.11	-11.05	102.86	194.52	320.53
Adjustment	27.52	46.23	71.31	93.40	107.62
Changes In working Capital	-15.58	-108.11	-135.08	-90.00	-114.60
Cash Flow after changes in Working Capital	-54.17	-72.93	39.08	197.93	313.56
Cash Flow from Operating Activities	-62.63	-74.75	21.01	159.18	205.05
Cash Flow from Investing Activities	-54.92	-33.82	-68.51	-64.81	-409.72
Cash Flow from Financing Activitie	63.05	122.81	43.55	-39.81	283.07
Net Cash Inflow / Outflow	-54.50	14.24	-3.95	54.56	78.39
Opening Cash & Cash Equivalents	84.16	38.67	54.43	50.60	104.98
Effect of Foreign Exchange Fluctuations	9.01	1.51	0.13	-0.19	2.29
Closing Cash & Cash Equivalent	38.67	54.43	50.60	104.98	185.65

Ratios

Valuation

101.30

21.75

62.87

15.08

17.41

81.09

Profitability

27.84

29.22

13.11

10.55

6.52

Leverage & Liquidity

0.21

2.01

8.60

Returns

0.09

2.01

Shareholding Pattern

Numbers in percentages

Particulars	Oct '25	Dec '25	Mar '26	Jun '26
	59.99	59.99	59.86	59.76
	19.12	17.43	17.56	16.95
	20.89	22.58	22.58	23.30
	40.01	40.01	40.14	40.24
No. of Shareholders	1,05,311	31,914	33,738	43,254

Corporate Actions

Showing: All

Date	Type	Details	Ex-Date	Record Date
2026-08-07	Board Meeting	Quarterly Results
2026-05-29	Ex Dividend	Rs.1.5000 per share(150%)Final Dividend	2026-08-07	2026-08-07
2026-05-22	Board Meeting	Final Dividend & Audited Results

Insider Trading

Date	Person	Category	Transaction Type	Shares
2026-09-15	GIRISH SUBRAMANIAM IYER	Market	Sell	1,500
2026-09-15	GIRISH SUBRAMANIAM IYER	Market	Sell	1,000
2026-09-15	GIRISH SUBRAMANIAM IYER	Market	Sell	1,296
2026-09-15	GIRISH SUBRAMANIAM IYER	Market	Sell	3,000
2026-09-04	Vinayak Sawant	Market	Buy	1,100
2026-08-28	General Atlantic Singapore RR Pte Ltd	Market	Sell	146,927
2026-08-28	General Atlantic Singapore RR Pte Ltd	Market	Sell	13,853,073
2026-08-25	Sanjay Renapurkar	Market	Sell	4,000
2026-08-25	Sanjay Renapurkar	Market	Sell	2,000
2026-07-01	Girish Subramaniam Iyer	Market	Sell	10,000
2026-06-30	Prakash Chandran	Market	Sell	20,000
2026-06-23	DINESH BHASKAR RAJADHYAX	Market	Sell	2,282
2026-06-17	Vinayak Sawant	Market	Sell	600
2026-06-17	Rajendra Mhaske	Market	Sell	3,000
2026-06-17	Vinayak Sawant	Market	Sell	1,400
2026-06-17	Vinayak Sawant	Market	Sell	780
2026-06-17	Rajendra Mhaske	Market	Sell	50
2026-06-17	Rajendra Mhaske	Market	Sell	2,000
2026-06-17	Rajendra Mhaske	Market	Sell	1,000
2026-06-17	Rajendra Mhaske	Market	Buy	16

Sector Overview

HealthcarePharmaceuticals & Drugs

Rubicon Research Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

14 members across the board and senior leadership

Deepashree Tanksale

Company Secretary & Compliance Officer

—

Pratibha Pilgaonkar

Managing Director

₹1.76 Cr

Mar '26

Pratibha Sudhir Pilgaonkar

Managing Director

—

Parag Suganchand Sancheti

Whole Time Director & CEO

₹5.60 Cr

Mar '26

Venkat Changavalli

Chairman

₹25.00 L

Mar '26

Pratik Umesh Shah

Company Secretary

—

K G Ananthakrishnan